keyword
https://read.qxmd.com/read/38468479/economic-burden-of-systemic-lupus-erythematosus-in-malaysia
#21
JOURNAL ARTICLE
Gihan Hamdy Elsisi, Ang Yu Joe, Mollyza Mohd Zain, Habibah Mohd Yusoof, Cheng Lay Teh, Asmah Binti Mohd, Xiang Ting Khor, Liza Binti Mohd Isa
INTRODUCTION: Our cost-of-illness (COI) model adopted the perspective of both payer and society over a time horizon of 5 years to measure the economic burden of systemic lupus erythematosus (SLE) in Malaysia. METHODOLOGY: Our COI model utilized a prevalence-based model to estimate the costs and economic consequences of SLE in Malaysia. The clinical parameters were obtained from published literature and validated using the Delphi panel. Direct and indirect medical costs were measured, including disease management, transient events, and indirect costs...
2024: Journal of Medical Economics
https://read.qxmd.com/read/38468478/clinical-and-economic-burden-of-systemic-lupus-erythematosus-in-colombia
#22
JOURNAL ARTICLE
Gihan Hamdy Elsisi, Gerardo Quintana, Diana Gil, Pedro Santos, Diana Fernandez
AIMS: Our cost-of-illness (COI) model adopted payer and societal perspectives over five years to measure the economic burden of Systemic Lupus Erythematosus (SLE) in Colombia. MATERIALS AND METHODS: A prevalence-based model was constructed to estimate costs and economic consequences for SLE patients in Colombia. The model included four health states: three phenotypes of SLE representing mild, moderate, and severe states and death. The clinical inputs were captured from the published literature and validated by the Delphi panel...
2024: Journal of Medical Economics
https://read.qxmd.com/read/38468477/the-economic-burden-of-systemic-lupus-erythematosus-in-mexico
#23
JOURNAL ARTICLE
Gihan Hamdy Elsisi, Lilia Andrade-Ortega, Margarita Portela, Gabriel Medrano Ramírez
AIMS: Our cost of illness study aimed to provide an estimate of the burden related to systemic lupus erythematosus (SLE) in the Mexican context. METHODS: Our model was used to simulate the resource utilization and economic consequences over a period of 5 years for patients with SLE in Mexico. The model simulated four health states-three phenotypes of SLE, including mild, moderate, and severe states, and death. Clinical parameters were retrieved from the literature...
2024: Journal of Medical Economics
https://read.qxmd.com/read/38464849/primary-immune-thrombocytopenic-purpura-itp-and-itp-associated-with-systemic-lupus-erythematosus-a-review-of-clinical-characteristics-and-treatment-modalities
#24
REVIEW
Krishna Prasad Bashyal, Sangam Shah, Calvin Ghimire, Shravya Balmuri, Pradip Chaudhary, Sandip Karki, Anuj Krishna Poudel, Ashbina Pokharel, Vishal Devarkonda, Samina Hayat
Immune thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by the destruction of platelets and megakaryocytes due to autoantibodies against the platelet surface proteins. ITP without any apparent cause of thrombocytopenia is defined as primary ITP, and ITP in the setting of SLE is secondary ITP, which can be diagnosed after excluding other causes of thrombocytopenia by history, physical examination, and laboratory testing. Patients with ITP associated with SLE have higher median platelet count and less bleeding manifestations compared to the patients with primary ITP...
2024: International Journal of Rheumatology
https://read.qxmd.com/read/38459603/effect-of-remission-clinical-remission-with-active-serology-and-glucocorticoid-dosage-on-the-pregnancy-outcome-of-pregnant-patients-with-systemic-lupus-erythematosus
#25
JOURNAL ARTICLE
Takehiro Nakai, Nanase Honda, Eri Soga, Sho Fukui, Ayako Kitada, Naoto Yokogawa, Masato Okada
BACKGROUND: Remission is a key treatment target in systemic lupus erythematosus (SLE) management. Given the direct correlation between lupus flares and elevated risks of adverse pregnancy outcomes (APOs), securing remission before conception becomes crucial. However, the association between clinical remission with active serology, and the risk of APOs is not thoroughly understood. Additionally, determining the optimal glucocorticoid dosage during pregnancy to mitigate APO risks remains under-researched...
March 9, 2024: Arthritis Research & Therapy
https://read.qxmd.com/read/38459403/assessing-the-steroid-sparing-effect-of-biological-agents-in-randomized-controlled-trials-for-lupus-a-scoping-review
#26
REVIEW
Savino Sciascia, Silvia Grazietta Foddai, Marta Arbrile, Massimo Radin, Irene Cecchi, Alice Barinotti, Roberta Fenoglio, Dario Roccatello
Prompt disease control of flares in patients with systemic lupus erythematosus (SLE) is a priority in treatment strategy planning. However, the long-term dosage-related collateral effects of glucocorticoids (GCs) have pushed researchers towards the identification and utilization of novel biological agents that could both induce and maintain low disease activity and remission, especially in the context of lupus nephritis (LN). This scoping review aims at assessing the current evidence of the potential steroid-sparing effect of biologic therapies by reviewing phase II and phase III randomized, placebo-controlled trials involving SLE/LN patients...
March 9, 2024: Immunologic Research
https://read.qxmd.com/read/38451142/neuromodulation-with-aerobic-exercise-reduces-fatigue-in-systemic-lupus-erythematosus-a-randomised-sham-controlled-double-blind-study
#27
JOURNAL ARTICLE
Vanessa P de Andrade, Alexandre M Dos Santos, Luciana P C Seguro, Emily F N Yuki, Michelle R U Lopes, Marcus V Grecco, Eduardo F Borba, Julia M A Greve, Samuel K Shinjo
OBJECTIVES: Transcranial direct current stimulation (tDCS) combined with aerobic exercise (tDCS-AE) effectively reduces fatigue in patients with fibromyalgia. However, no study has assessed this method in systemic lupus erythematosus (SLE) patients with significant fatigue. Therefore, we evaluated the safety and efficacy of tDCS-AE for significant fatigue symptoms in adult female SLE patients. METHODS: This randomised, sham-controlled, double-blind study included 25 patients with SLE in remission or low disease activity (SLEDAI-2K £4) and with significant fatigue [≥36 points on the Fatigue Severity Scale (FSS) or ≥38 points on the Modified Fatigue Scale (MFIS)]...
March 7, 2024: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/38447695/issues-with-pregnancy-in-systemic-lupus
#28
JOURNAL ARTICLE
Véronique Le Guern, Gaelle Guettrot-Imbert, Anastasia Dupré, Sandrine Perol, Emmanuelle Pannier, Nathalie Morel, Nathalie Costedoat-Chalumeau
Systemic lupus erythematosus is a disease that affects a large number of young women of childbearing age. Today, pregnancy is considered safe in almost all women with lupus, especially when the disease is under control. However, pregnancies in this population have a higher risk of maternal complications than in the general population. It is therefore important to plan pregnancies as effectively as possible, using effective contraception and pre-pregnancy counselling. In fact, effective, well-tolerated contraception is essential for patients for whom pregnancy cannot be safely envisaged, particularly in the setting of teratogenic treatment or significant disease activity...
March 4, 2024: Joint, Bone, Spine: Revue du Rhumatisme
https://read.qxmd.com/read/38433189/natural-language-processing-to-identify-lupus-nephritis-phenotype-in-electronic-health-records
#29
JOURNAL ARTICLE
Yu Deng, Jennifer A Pacheco, Anika Ghosh, Anh Chung, Chengsheng Mao, Joshua C Smith, Juan Zhao, Wei-Qi Wei, April Barnado, Chad Dorn, Chunhua Weng, Cong Liu, Adam Cordon, Jingzhi Yu, Yacob Tedla, Abel Kho, Rosalind Ramsey-Goldman, Theresa Walunas, Yuan Luo
BACKGROUND: Systemic lupus erythematosus (SLE) is a rare autoimmune disorder characterized by an unpredictable course of flares and remission with diverse manifestations. Lupus nephritis, one of the major disease manifestations of SLE for organ damage and mortality, is a key component of lupus classification criteria. Accurately identifying lupus nephritis in electronic health records (EHRs) would therefore benefit large cohort observational studies and clinical trials where characterization of the patient population is critical for recruitment, study design, and analysis...
March 3, 2024: BMC Medical Informatics and Decision Making
https://read.qxmd.com/read/38428956/flare-in-systemic-lupus-erythematosus-lost-in-translation
#30
EDITORIAL
Eric F Morand, Sarah A Jones
The concept of systemic lupus erythematosus (SLE) as a relapsing and remitting condition is deeply embedded in how clinicians perceive this disease. This perception arises from observations of periods of low disease activity interspersed with episodes of more active disease, which are commonly referred to as "flares."
March 1, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38423757/risk-of-flare-and-damage-accrual-after-tapering-glucocorticoids-in-modified-serologically-active-clinically-quiescent-patients-with-systemic-lupus-erythematosus-a-multinational-observational-cohort-study
#31
JOURNAL ARTICLE
Yasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, Jiacai Cho, Worawit Louthrenoo, Alberta Hoi, Vera Golder, Chak Sing Lau, Aisha Lateef, Yi-Hsing Chen, Shue-Fen Luo, Yeong-Jian Jan Wu, Laniyati Hamijoyo, Zhanguo Li, Sargunan Sockalingam, Sandra Navarra, Leonid Zamora, Yanjie Hao, Zhuoli Zhang, Madelynn Chan, Shereen Oon, Kristine Ng, Jun Kikuchi, Tsutomu Takeuchi, Fiona Goldblatt, Sean O'Neill, Nicola Tugnet, Annie Hui Nee Law, Sang-Cheol Bae, Yoshiya Tanaka, Naoaki Ohkubo, Sunil Kumar, Rangi Kandane-Rathnayake, Mandana Nikpour, Eric F Morand
OBJECTIVES: To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE). METHODS: Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ defined as the state with serological activity (increased anti-dsDNA and/or hypocomplementemia) but without clinical activity, treated with ≤7...
February 29, 2024: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/38420060/deciphering-the-neuropsychiatric-lupus-enigma-navigating-the-intersection-of-acute-inflammatory-demyelinating-polyneuropathy-aidp-infection-and-flare
#32
Jhasaketan Meher, Jivtesh Singh, Saroj Kumar Pati, Vinay R Pandit, Saurabh K Patel, Mallika Kapur, M S Nithin
A 17-year-old male diagnosed with systemic lupus erythematosus (SLE), showing poor compliance with medication, presented to our facility with a 20-day history of fever, polyarthritis, and cough. Additionally, he had experienced a seizure episode, followed by a one-day history of altered mentation. Subsequently, he developed pneumonia, respiratory distress, and shock, necessitating ventilator and inotropic support. Neuropsychiatric lupus (NP-lupus) was suspected, and hence high-dose steroids, hydroxychloroquine, and broad-spectrum antibiotics were initiated...
January 2024: Curēus
https://read.qxmd.com/read/38405595/case-report-in-situ-pulmonary-artery-thrombosis-in-a-12-year-old-girl-classified-as-systemic-lupus-erythematosus
#33
Yong Feng, Ning Chen, Bing Dai, Yunxiao Shang
In situ pulmonary artery thrombosis (ISPAT) is a relatively rare but potentially life-threatening complication of systemic lupus erythematosus (SLE) in children. We report the case of a 12-year-old girl who presented with fever, chest pain, and dyspnea. Immune thrombocytopenia was identified due to purpura and menorrhagia 3 months before presentation with a lowest platelet count of 12 × 109 /L. The sudden onset of fever, chest pain, and dyspnea were misdiagnosed as hyperinflammatory responses caused by pneumonia; these symptoms ameliorated with glucocorticoid and antibiotic treatment...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38399467/immune-checkpoint-inhibitors-and-lupus-erythematosus
#34
REVIEW
Hans Vitzthum von Eckstaedt, Arohi Singh, Pankti Reid, Kimberly Trotter
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number of malignancies. Unfortunately, they are associated with a broad range of unique toxicities that mimic the presentations of primary autoimmune conditions. These adverse events are termed immune-related adverse events (irAEs), of which ICI-lupus erythematosus (ICI-LE) constitutes a small percentage. Our review aims to describe the available literature on ICI-LE and ICI treatment for patients with pre-existing lupus. Most diagnoses of ICI-LE had findings of only cutaneous lupus; four diagnoses of ICI-LE had systemic lupus manifestations...
February 15, 2024: Pharmaceuticals
https://read.qxmd.com/read/38335115/immunogenicity-and-safety-of-bnt162b2-vaccination-in-adolescents-with-systemic-lupus-erythematosus
#35
JOURNAL ARTICLE
Nuntawan Piyaphanee, Sirirat Charuvanij, Sutheera Thepveera, Zheng Quan Toh, Paul V Licciardi, Anirut Pattaragarn, Patimaporn Wongprompitak, Kobporn Boonnak, Chatkamol Pheerapanyawaranun, Kulkanya Chokephaibulkit
OBJECTIVES: We evaluated the immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus (adoSLE) receiving either high- or low-dose immunosuppressant (High-IS and Low-IS). METHODS: Patients aged 12-18 years diagnosed with SLE were enrolled. High-IS was defined as >7.5 mg/day prednisolone or with other immunosuppressant, while Low-IS was defined as only ≤7.5 mg/day of prednisolone and no immunosuppressant...
February 9, 2024: Lupus
https://read.qxmd.com/read/38333243/successful-pregnancy-after-cyclophosphamide-therapy-for-systemic-lupus-erythematosus-a-case-report
#36
Tasneem Drie, Mhd Imadaldin Alsamman, Raghad Tarcha, Ghina Haidar, Maysoun Kudsi
INTRODUCTION AND IMPORTANCE: The use of cyclophosphamide in women of childbearing age with severe systemic lupus erythematosus is normally indicated. However, cyclophosphamide is generally avoided during pregnancy due to the risk of teratogenicity, especially since its effect on fetal survival is poorly understood. This is a case report of a lupus patient exposed to cyclophosphamide during pregnancy. CASE PRESENTATION: A 35-year-old woman with a history of lupus presented to our outpatient clinic in the 12th week of pregnancy for her sixth routine cyclophosphamide bolus...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38333242/systemic-lupus-erythematosus-and-down-syndrome-a-case-report-and-literature-review
#37
Maysoun Kudsi, Diaa Haj Ali, Naram Khalayli, Samah Jaber, Rama Nasser Mansour Almasri
INTRODUCTION: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can involve any organ system, and may lead to significant morbidity and even mortality. Down syndrome (DS) is the most frequent genetic cause of intellectual disabilities, typically caused by the presence of an extra chromosome 21. CASE PRESENTATION: A 47-year-old Syrian female of DS who complained of low-grade fever, oral aphthae, fatigue, and arthralgia three months before presentation...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38328232/epidermal-zbp1-stabilizes-mitochondrial-z-dna-to-drive-uv-induced-ifn-signaling-in-autoimmune-photosensitivity
#38
Benjamin Klein, Mack B Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Yiqing Gao, Celine C Berthier, Svenja Henning, Shannon N Loftus, Kelsey E McNeely, Amanda M Victory, Craig Dobry, Grace A Hile, Feiyang Ma, Jessica L Turnier, Johann E Gudjonsson, Mary X O'Riordan, J Michelle Kahlenberg
Photosensitivity is observed in numerous autoimmune diseases and drives poor quality of life and disease flares. Elevated epidermal type I interferon (IFN) production primes for photosensitivity and enhanced inflammation, but the substrates that sustain and amplify this cycle remain undefined. Here, we show that IFN-induced Z-DNA binding protein 1 (ZBP1) stabilizes ultraviolet (UV)B-induced cytosolic Z-DNA derived from oxidized mitochondrial DNA. ZBP1 is significantly upregulated in the epidermis of adult and pediatric patients with autoimmune photosensitivity...
January 26, 2024: bioRxiv
https://read.qxmd.com/read/38317756/kidney-biopsy-in-management-of-lupus-nephritis-a-case-based-narrative-review
#39
REVIEW
Sonia Rodriguez-Ramirez, Nasim Wiegley, Juan Manuel Mejia-Vilet
Kidney involvement in patients with lupus highly increases morbidity and mortality. In recent years, several reports have emphasized the dissociation between clinical and histological findings and highlighted the role of kidney biopsy as an instrument for diagnosis and follow-up of lupus nephritis. The kidney biopsy at initial diagnosis allows an early diagnosis, assessment of activity and chronicity, and detection of nonimmune complex nephritis. A kidney biopsy repeated months after treatment aids in the detection of persistent histological inflammation, which has been linked to the occurrence of future kidney relapses...
February 2024: Kidney medicine
https://read.qxmd.com/read/38317519/the-impact-of-hormones-in-autoimmune-cutaneous-diseases
#40
REVIEW
Lais Lopes Almeida Gomes, Adrienne J Werth, Preethi Thomas, Victoria P Werth
INTRODUCTION: Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and these two skin diseases. MATERIALS AND METHODS: We performed an extensive literature search using the PubMed database from July to August 2023. Search terms included 'contraceptives', 'pregnancy', 'hormone replacement', 'tamoxifen', and 'aromatase inhibitors'...
December 2024: Journal of Dermatological Treatment
keyword
keyword
164516
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.